Our vision consists of revolutionizing dental and orthopedic surgery by introducing a new paradigm, model-based theranostics, which consists of an integrative coupling of therapeutics, diagnostics and numerical simulation in order to optimize the performances of the surgical protocol and to predict its clinical outcome. The success of surgical protocols involving endosseous implants is limited by i) the empirical methods employed to assess implant stability, which is a strong determinant of the surgical outcome, ii) the absence of therapeutic approaches to stimulate osseointegration phenomena and iii) the difficulty of predicting the implant outcome. The aim of UltraSimplant is to develop a radically new unified model-based theranostic concept using innovative ideas in the domain of quantitative ultrasound (QUS). The new concept will combine characterization, simulation and stimulation of osseointegration phenomena, leading to the foundation of a revolutionary approach capable of providing a decision support system to the surgeon, to improve osseointegration in a patient specific manner and to predict the surgical outcome, thus leading to a drastic decrease of the implants failure rate. We will conceive and validate (in vitro, in silico, in vivo and in a clinical trial) a minimum viable product and consisting of a medical device using QUS techniques to assess dental implant stability. A validated model of the evolution of the bone-implant system will take into account the complex multiscale nature of the interface in order to validate in silico the QUS device and to predict the effect of ultrasound stimulation and implant outcome. The model will be used in order to optimize the parameters to be employed in the stimulation. UltraSimplant will first focus on dental implants because of the important failure rate and to the easy access of the implant. In the long term, model-based theranostic approaches will be applied to other implants in orthopedic surgery.